{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:00:58Z","timestamp":1789884058240,"version":"4.0.1"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T00:00:00Z","timestamp":1255046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T00:00:00Z","timestamp":1255046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologica"],"abstract":"<jats:p>The purpose of this double-blind study was to compare the therapeutic effects of a low initial dosage of acitretin, increased at 2-week intervals (group 1:10, 30, 50 mg\/day) with a high initial dosage decreased at similar intervals (group 3: 50, 30, 10 mg\/day) and with a constant dosage (group 2: 30 mg\/day) in 66 patients (47 men and 19 women) with severe psoriasis. At the end of the double-blind phase the mean percent improvement calculated by the Psoriasis Area and Severity Index score, was as follows: 62.7% in group 1, 55.9% in group 2 and 67.1% in group 3.The double-blind phase of 6 weeks was followed by an open phase of 6 weeks, during which the patients were treated either with 10, 30 or 50 mg\/day, according to the therapeutic response. At the end of treatment (12 weeks), a mean improvement of more than 80% was obtained in all three groups. Hypervitaminosis A signs and symptoms were observed in all patients. The frequency and severity of these adverse reactions were shown to be dose-dependent. This study shows that a low dose progressively increased is advisable because of similar activity and better acceptability.<\/jats:p>","DOI":"10.1159\/000248398","type":"journal-article","created":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T01:54:47Z","timestamp":1255398887000},"page":"88-92","source":"Crossref","is-referenced-by-count":43,"title":["Benefit of Progressively Increasing Doses during the Initial Treatment with Acitretin in Psoriasis"],"prefix":"10.1159","author":[{"given":"P.","family":"Berbis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vaisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rognin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Privat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,10,9]]},"container-title":["Dermatologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/248398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000248398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:33:02Z","timestamp":1777541582000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000248398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000248398","archive":["Portico"],"relation":{},"ISSN":["0011-9075","2571-7197"],"issn-type":[{"value":"0011-9075","type":"print"},{"value":"2571-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,9]]}}}